Drugs / EDP-978
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07540910 | Apr → Nov 2026 expected | chronic inducible urticaria | Enanta Pharmaceuticals, Inc | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-13 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria enanta.com ↗ |
| 2026-02-10 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting enanta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-978 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07540910 ↗ |
| Route | Oral | “Oral administration” NCT07540910 ↗ |